US wait times for cancer surgeries are getting longer and longer

The numbers are unambiguous. A decade of progress in cancer care has been accompanied by a steady erosion in one of its most basic promises: getting the patient to the operating room on time. The JAMA Surgery study, covering more than 2.7 million patients across six major cancer types, shows that wait times in 2022–2023 were the longest in ten years. That is not a blip. It is a trend line.

The study’s design is straightforward, which makes its findings harder to dismiss. By dividing the period into four blocks, the researchers isolate the effect of the pandemic without letting it obscure the longer arc. The 2020–2021 spike is real, but the data show the problem predates COVID-19 and has not receded since. The system was already straining before the crisis, and the crisis made the strain structural.

What is driving the delay? The study points to a familiar set of pressures: an aging population, a surgeon shortage, and hospital capacity that has not kept pace with demand. But there is a subtler force at work. As treatments have improved, more patients are eligible for surgery. The pool of candidates has grown, and the infrastructure to serve them has not. The result is a queue that lengthens even as outcomes improve—a paradox that is cold comfort to the patient waiting for a date.

The clinical stakes are well documented. Delays in cancer surgery are linked to worse survival and greater psychological distress. The anxiety of waiting is not a side effect; it is a symptom of a system that has quietly deprioritized timeliness. For the individual patient, the wait is not an abstraction. It is weeks of uncertainty, of watching the calendar, of wondering whether the tumor is growing while the paperwork moves.

For those who track labor markets, the signal is equally clear. The bottleneck is not a lack of demand or a failure of technique. It is a shortage of surgeons and operating room capacity—human and physical capital that cannot be conjured overnight. Training a surgeon takes a decade. Building an OR takes years and billions. The wait times are not a temporary glitch; they are the output of a pipeline that was underfunded and understaffed long before this study was conceived.

The study’s authors call timeliness a core metric of quality. That is a quiet way of saying that a system that makes patients wait is failing them, regardless of how advanced its treatments are. The data suggest the failure is not accidental. It is the predictable result of choices made over many years about how many surgeons to train, how many ORs to build, and how much to invest in the logistics of care.

None of this is new to anyone who has worked in a hospital. But the study converts anecdote into evidence, and evidence into a verdict. The wait times are not getting better. They are getting longer, and the trend has persisted through boom, bust, and pandemic. The question is not whether the system is broken—it is whether anyone is willing to pay the price to fix it.